News

Filter

Current filters:

HerceptinPricing

NICE views breast cancer drugs from GSK and Roche too expensive

14-02-2012

The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

EuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

UK NICE says benefits of breast cancer drugs Tyverb and Herceptin still unproven

03-07-2011

In a draft guidance issued last Friday, the UK’s drug watchdog, the National Institute for Health…

GlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

More NICE rejections, for Roche’s Avastin and Herceptin and GlaxoSmithKline’s Tyverb

15-12-2010

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued final guidance…

AvastinEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

Roche convinces UK’s NICE to recommend Herceptin for metastatic gastric cancer; Novartis fail in higher dose Glivec

25-11-2010

The UK’s drug watchdog, the National Institute for Health and Clinical Excellence (NICE), this week…

EuropeGlivecHerceptinNovartisOncologyPharmaceuticalPricingRegulationRoche

Back to top